Medicine is shifting. The nose knows.

Olfax Medical develops and commercializes nasally administered, direct to nerve therapeutics for patients with diseases treated by ear, nose, and throat (ENT) and neurology specialists.

Our products and development pipeline are based on the nasal Automizer^TM platform, a simple-to-use, handheld device designed to accurately deliver multiple doses of highly controlled, aerosolized medication to the highly vascularized upper-posterior nasal cavity without the use of propellants.

Nasal drug administration has traditionally focused on systemic drugs that are absorbed into the bloodstream.  The Automizer^TM makes use of the nasal turbinate nerve network’s (olfactory and trigeminal nerves) ability to absorb neurologically active medications directly from the nose to the brain, bypassing the blood-brain barrier. This “nose to brain” approach improves treatment options for neurological diseases and enables optimization and simplification of therapeutic molecules and formulations to reduce the need for blood absorption enhancing adjuvants and, in turn, the potential for undesirable side effects.